免疫检查点抑制剂相关皮肤毒性:一项观察性药物警戒研究
基于世界卫生组织VigiBase数据库的观察性药物警戒研究,比较91,323例免疫检查点抑制剂相关不良事件与全库18,919,358例不良事件,识别出10,933例皮肤免疫相关不良事件,涵盖51种皮肤类型,27种皮疹呈 disproportionate 信号,其中8种报告数>100,且不同皮疹发作时间不同。
要点
- 皮肤免疫相关不良事件共10,933例,涉及51种皮肤类型,27种皮疹有 disproportionate 信号(IC025>0)。
- 8种皮疹报告数>100,包括白癜风(IC025=4.87)、大疱性类天疱疮(IC025=4.08)等。
- 不同皮疹发作时间不同:多形红斑、Stevens-Johnson综合征和中毒性表皮坏死松解症中位约1个月,药疹和湿疹性皮炎约2个月,苔藓样皮炎约4个月,大疱性类天疱疮和白癜风约5-6个月。
核心结论
- 皮肤免疫相关不良事件多样,取决于癌症类型,且不同亚型有不同发作时间。
研究设计与样本
- 观察性药物警戒研究,使用世界卫生组织VigiBase数据库(来自130多个成员国的个体病例安全报告全球数据库),临床试验注册号NCT04898751。
- 比较接受免疫检查点抑制剂患者的91,323例不良事件与全报告数据库的18,919,358例不良事件。
主要发现
- 共识别10,933例皮肤免疫相关不良事件,涵盖51种 distinct 皮肤类型。
- 27种特定皮疹呈现 disproportionate 信号(信息成分[IC]025 > 0)。
- 27种皮疹中8种报告数>100:白癜风(IC025=4.87)、大疱性类天疱疮(IC025=4.08)、苔藓样皮炎(IC025=3.69)、多形红斑(IC025=1.03)、中毒性表皮坏死松解症(IC025=0.95)、Stevens-Johnson综合征(IC025=0.41)、药疹(IC025=0.11)、湿疹性皮炎(IC025=0.11)。
- 免疫检查点抑制剂启动后发作时间中位数:多形红斑、Stevens-Johnson综合征和中毒性表皮坏死松解症约1个月;药疹和湿疹性皮炎约2个月;苔藓样皮炎约4个月;大疱性类天疱疮和白癜风约5-6个月。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cutaneous immune-related adverse events (cirAEs) are the most prevalent complication to arise from immunotherapy and cause significant morbidity. We aimed to determine the spectrum, timing, clinical features, and outcomes of cirAEs by conducting an observational pharmacovigilance study using VigiBase, the World Health Organization's global database of individual case safety reports from over 130 member countries (ClinicalTrials.gov, number NCT04898751). We compared adverse event reporting in patients who received immune checkpoint inhibitors (91,323 adverse events) with those of the full reporting database (18,919,358 adverse events). There were 10,933 cases of cirAEs within 51 distinct dermatologic types, with 27 specific eruptions with disproportionate signal represented (information component [IC]025 > 0). Of these 27 eruptions, there were eight cirAEs with n > 100 reports, including vitiligo (IC025 = 4.87), bullous pemphigoid (IC025 = 4.08), lichenoid dermatitis (IC025 = 3.69), erythema multiforme (IC025 = 1.03), toxic epidermal necrolysis (IC025 = 0.95), Stevens‒Johnson syndrome (IC025 = 0.41), drug eruption (IC025 = 0.11), and eczematous dermatitis (IC025 = 0.11). There were differences in time to onset after immune checkpoint inhibitor initiation, with a median of approximately 1 month (erythema multiforme, Stevens‒Johnson syndrome, and toxic epidermal necrolysis), 2 months (drug eruption and eczematous dermatitis), 4 months (lichenoid dermatitis), and 5‒6 months (bullous pemphigoid and vitiligo). CirAEs are diverse, dependent on cancer type, and have distinct and different onset times that are linked to the cirAE subtype.
引用
- Le TK, Brown I, Goldberg R, et al. Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study. J Invest Dermatol. 2022. PMID: 35605659. doi:10.1016/j.jid.2022.04.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。